1-4 of 4
Richard E. Clark
Close
Sort by
Journal Articles

Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients

Mike Dennis, Ian F. Thomas, Cono Ariti, Laura Upton, Alan K. Burnett, Amanda Gilkes, Rohini Radia, Claire Hemmaway, Priyanka Mehta, Steven Knapper, Richard E. Clark, Mhairi Copland, Nigel Russell, Robert K. Hills
Journal: Blood Advances
Blood Adv (2021) 5 (24): 5621–5625.
https://doi.org/10.1182/bloodadvances.2021005038
Published: 2021
Includes: Supplemental data
Journal Articles

Additional chromosomal abnormalities at chronic myeloid leukemia diagnosis predict an increased risk of progression

Clinical Trials & Observations
Richard E. Clark, Jane F. Apperley, Mhairi Copland, Silvia Cicconi
Journal: Blood Advances
Blood Adv (2021) 5 (4): 1102–1109.
https://doi.org/10.1182/bloodadvances.2020003570
Published: 2021
Includes: Supplemental data
Journal Articles

CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML

Claire M. Lucas, Laura J. Scott, Natasha Carmell, Alison K. Holcroft, Robert K. Hills, Alan K. Burnett, Richard E. Clark
Journal: Blood Advances
Blood Adv (2018) 2 (9): 964–968.
https://doi.org/10.1182/bloodadvances.2017013615
Published: 2018
Includes: Supplemental data
Journal Articles

Heterogeneous leukemia stem cells in myeloid blast phase chronic myeloid leukemia

Ross Kinstrie, Dimitris Karamitros, Nicolas Goardon, Heather Morrison, Mike Hamblin, Lisa Robinson, Richard E. Clark, Mhairi Copland, Paresh Vyas
Journal: Blood Advances
Blood Adv (2016) 1 (3): 160–169.
https://doi.org/10.1182/bloodadvances.2016000810
Published: 2016
Includes: Supplemental data